Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q2 2026 · 10-Q
Revenue$183.58M$183.58M+15.6% vs Q2 2025 Net Income-$15.66M-$15.66MN/M vs Q2 2025 EPS Diluted-$0.13-$0.13N/M vs Q2 2025 Gross Profit$142,478,000+21.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow$8,132,000N/M Free Cash Flowderived$1,216,000N/M Margins · derivedGross margin77.6%+3.7 pt vs Q2 2025
Operating margin-5.8%+19.1 pt vs Q2 2025
Net margin-8.5%+16.7 pt vs Q2 2025
ended Jun 30, 2026 · filed Jul 23, 2026 · 23 d after period end